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S216 Oral Presentationsunits homozygous for the CCR5-delta32 allele will provide an im-
proved probability of finding an appropriately HLA-matched donor
for a patient with HIV infection in need of a HCT.
Methods: CCR5 genotype analysis is performed on DNA extracted
from cord blood using a PCR based assay. Biomathematicians at the
NMDP developed estimates regarding the probability of providing
an adequately HLA matched cord blood unit.
Results: We have tested about 10,000 cryopreserved cord blood
units and have identified 81 homozygous CCR5-delta32 units.
Testing an additional 25,000 cord blood units from Caucasians
is expected to increase the special inventory to about 300 units
which is projected to provide for Caucasians an adequately
HLA matched cord blood unit with an adequate cell dose for
73.61% of pediatric patients and 27.92% of adults. The initial
population for transplantation is patients in need of a HCT for
a hematologic malignancy or other indication, and who are also
infected with HIV, although some selected patients with AIDS
who have no other illness may also ultimately be considered for
transplantation.
Conclusions: Cord blood transplantation has a unique role in pro-
viding for long term control or possible cure of HIV infection.
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LONG TERM OUTCOMES FOR ALEMTUZUMAB BASED REDUCED INTEN-
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Marsh, J.C., Pagliuca, A., Ghulam,M.J. Kings College Hospital, London,
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Haematopoietic Stem Cell Transplantation (HSCT) remains
the only curative therapy for patients with myelodysplastic syn-
dromes (MDS) and acute myeloid leukaemia with tri-lineage dys-
plasia (TLD-AML). Reduced intensity conditioning (RIC) has
expanded this approach to older patients and to those with co-
morbidities. Previously published data from our institution has
shown excellent overall survival and low rates of GVHD at one
year with alemtuzumab-based RIC-HSCT. Herein we report
the long-term follow-up data of 237 patients with high risk
MDS and TLD-AML treated at our institution from 1999 to
June 2010.
All patients received a conditioning protocol consisting of fludar-
abine (150mg/m2), busulphan and alemtuzumab (100mg) from sib-
ling (n 5 57) or matched unrelated donors (MUD) (n 5 180). 30
patients received 4 days of busulphan (total dose 12.8mg/kg iv or
16mg po) while the remainder received 2 days (total dose 6.4mg/
kg iv 8mg po). The majority of patients receiving an unrelated
transplant had a fully matched donor (n 5 128), with 45 having
a 1-antigen mm donor and 7 having a 2-antigen mm donor. The
median age of the cohort was 56 years (range:19-72) and median
follow-up for survivors was 5.2 years (range:0.12-11.4). OS and
DFS for the entire cohort was 44% and 34% respectively at five years
with no significant difference between sibling andMUD transplants.
NRM was 23% at one year and 31% at five years. Relapse at five
years was 51%. Acute GVHD occurred in 35% and chronic
GVHD in 27%. The rate of extensive de-novo chronic GVHD
was very low at 10%. Outcomes were similar for those receiving
four doses of busulphan despite a higher proportion of patients not
in CR at the time of HSCT in this group.
On multivariate analysis, age remained the only significant fac-
tor with regard to OS, DFS and NRM. For patients aged less than
60 vs greater than 60 years at five years OS was 55 vs 23%, DFS
was 46 vs 15% and NRM 27 vs 50%. To our knowledge this
analysis represents the largest series of patients receiving alemtu-
zumab based RIC for MDS and TLD-AML. Long-term out-
comes remain excellent for younger patients. Novel strategies
are required for the prevention of relapse and to improve out-
comes in older patients.37
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The Myeloproliferative Disorder-Research Consortium (MPD-
RC) designed the first US prospective phase II study of reduced in-
tensity allogeneic hematopoietic stem cell transplantation (HSCT)
in patients with primarymyelofibrosis (PMF) orMF secondary to es-
sential thrombocythemia (ET-MF) or polycythemia vera (PV-MF).
Between May 2007 and March 2011, 66 patients were enrolled into
MPD-RC 101 study and transplanted from related (n5 32) or unre-
lated (n 5 34) donors using a fludarabine/melphalan 6 ATG regi-
men. Of 66 patients, 63 were at intermediate/high risk according
to Lille score system and 3 low risk patients had thrombocytopenia.
Recipients of related and unrelatedHSCTwere comparable with re-
spect to age (median: 54 vs 55 years), gender, Lille score, time from
diagnosis to transplant, presence of Jak-2 V617F mutation, spleno-
megaly and splenectomy. Donors were HLA matched in 94% of re-
lated and 74% of unrelated transplants. Engraftment of neutrophils
and platelets occurred in 31/32 related and 26/34 unrelated trans-
plants. Five secondary graft failures occurred (4 among unrelated re-
cipients). Median time to ANC . 0.5 x 109/L and platelets .20 x
109/L engraftment was: day 22 and 28 in the related, and day 18
and 28 in the unrelated cohort, respectively. Acute GVHD grade
II-IV occurred in 37% related (grade III-IV: 12%) and 42% unre-
lated transplants (grade III-IV: 21%). In patients with $ 6 months
follow-up, there were 7 CR, 8 PR, and 11 CI according to the
IWG criteria among the 28 patients in the related group, and 5
CR, 1 PR, and 5 CI among the 16 patients in the unrelated group.
After a median follow-up of 24 months for survivors in the related
group, 78% of the patients are alive, TRM was 18% and relapse-re-
lated mortality was 3%. In the unrelated group, 44% of the patients
are alive after 12months follow-up, TRMwas 53% and 3% died due
to relapse. Median survival time has not been reached in the related
group and is 7 months in the unrelated group (hazard ratio 4.2, 95%
CI: 1.7-10.1, p\0.001). Survival in unrelated transplants was not as-
sociated with PBSC or BMHSCT, HLAmatching, diagnosis, Jak-2
mutation. In this prospective study a reduced intensity allogeneic
HSCTwith Flu/Mel regimen was very effective in myelofibrosis pa-
tients transplanted from related donors. In unrelated transplants,
a high rate of primary or secondary graft failure led to a high rate
of TRM. For these patients a different conditioning regimen may
be required.38
IDENTIFICATION AND CHARACTERIZATION OF H-Y SPECIFIC ALLOGE-
NEIC B CELLS FOLLOWING SEX-MISMATCHED TRANSPLANTATION
Sahaf, B., Perloff, S.H., Wu, F., Miklos, D.B. Division of Blood andMar-
row Transplantation, Stanford University School of Medicine
H-Y allo-antibody develop in association with chronic graft-ver-
sus-host disease (cGVHD) following sex-mismatched transplant.
We hypothesize that H-Y specific B cells contribute to cGVHD
pathogenesis and have developed H-Y specific FACS stain for their
isolation and characterization.
